EA201290956A1 - Вакцина против вич - Google Patents

Вакцина против вич

Info

Publication number
EA201290956A1
EA201290956A1 EA201290956A EA201290956A EA201290956A1 EA 201290956 A1 EA201290956 A1 EA 201290956A1 EA 201290956 A EA201290956 A EA 201290956A EA 201290956 A EA201290956 A EA 201290956A EA 201290956 A1 EA201290956 A1 EA 201290956A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hiv
vaccine against
against hiv
clade
antigens
Prior art date
Application number
EA201290956A
Other languages
English (en)
Inventor
Патрисья Бургиньон
Маргерит Кристин Кутсукос
Кларис Лорен
Лиза Макнэлли
Жераль Эрманн Восс
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201290956A1 publication Critical patent/EA201290956A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Изобретение относится к иммуногенным композициям, включающим антигены ВИЧ-1, и к их применению для терапии и/или профилактики ВИЧ-1. В частности, изобретение относится к применению антигенов ВИЧ-1 из одной клады для профилактики и/или терапии заболевания, ассоциированного с инфекцией ВИЧ-1 из гетерологичной клады ВИЧ-1.
EA201290956A 2010-03-26 2011-03-25 Вакцина против вич EA201290956A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31813010P 2010-03-26 2010-03-26
PCT/EP2011/054654 WO2011117408A1 (en) 2010-03-26 2011-03-25 Hiv vaccine

Publications (1)

Publication Number Publication Date
EA201290956A1 true EA201290956A1 (ru) 2013-04-30

Family

ID=44064896

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290956A EA201290956A1 (ru) 2010-03-26 2011-03-25 Вакцина против вич

Country Status (13)

Country Link
US (1) US20140234399A1 (ru)
EP (1) EP2552480A1 (ru)
JP (1) JP2013523617A (ru)
KR (1) KR20130063493A (ru)
CN (1) CN103221065A (ru)
AU (1) AU2011231574A1 (ru)
CA (1) CA2794558A1 (ru)
EA (1) EA201290956A1 (ru)
IL (1) IL222228A0 (ru)
MX (1) MX2012011189A (ru)
SG (1) SG184188A1 (ru)
WO (1) WO2011117408A1 (ru)
ZA (1) ZA201207030B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501225A (ja) * 2010-09-27 2014-01-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB201316463D0 (en) * 2013-09-16 2013-10-30 Giles Clark & Cook Ltd Novel compositions
GB201316464D0 (en) * 2013-09-16 2013-10-30 Giles Clark & Cook Ltd Novel compositions
CA2936086C (en) * 2014-01-08 2024-02-27 Immunovative Therapies, Ltd. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
WO2015147899A1 (en) * 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
CN106714800B (zh) 2014-07-11 2021-09-03 吉利德科学公司 用于治疗hiv的toll样受体调节剂
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) * 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
US20200276299A1 (en) * 2017-09-08 2020-09-03 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
CN114828884A (zh) * 2019-05-22 2022-07-29 埃利克斯疗法公司 用于疫苗的剂量方案

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
UA40597C2 (ru) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинная композиция, способ лечения млекопитающих, больных или восприимчивых к инфекции, способ лечения млекопитающих, больных на рак, способ получения вакцинной композиции, композиция адъювантов
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
JP4637356B2 (ja) 1998-08-04 2011-02-23 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 広い反応性の中和抗体応答を伴うｈｉｖ−１エンベロープタンパク質の発現およびキャクタライゼーション
MXPA06013093A (es) 2004-05-11 2007-08-08 Nederlanden Staat Lipo-oligo-sacarido de neisseria meningitidis igtb como adyuvante.
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions

Also Published As

Publication number Publication date
WO2011117408A1 (en) 2011-09-29
ZA201207030B (en) 2013-05-29
EP2552480A1 (en) 2013-02-06
MX2012011189A (es) 2013-02-07
KR20130063493A (ko) 2013-06-14
SG184188A1 (en) 2012-10-30
AU2011231574A1 (en) 2012-10-11
IL222228A0 (en) 2012-12-31
US20140234399A1 (en) 2014-08-21
CA2794558A1 (en) 2011-09-29
JP2013523617A (ja) 2013-06-17
CN103221065A (zh) 2013-07-24

Similar Documents

Publication Publication Date Title
EA201290956A1 (ru) Вакцина против вич
CY1124043T1 (el) Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
MD20200093A2 (ru) Полициклические соединения карбамоилпиридона и их фармацевтическое применение
PH12015501156A1 (en) Pharmaceutical compositions
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
EA201391515A1 (ru) Инактивированная вакцина вируса денге
IN2014KN02740A (ru)
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
EA201790495A1 (ru) Фармацевтические композиции длительного действия
MX343505B (es) Metodos y composiciones para inhibir la transmision del vih.
WO2012047267A3 (en) Polyvalent immunogen
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
WO2016100615A3 (en) Methods and composition for neutralization of influenza
WO2015086738A3 (en) Hiv vaccine
EA201390452A1 (ru) Вакцина
ZA202104746B (en) Novel trypanosomal vaccine
EA201300134A1 (ru) Фармацевтическая композиция и способ лечения и профилактики заболеваний, вызванных или связанных с вич